XNASCNSP
Market cap6mUSD
Dec 23, Last price
0.11USD
1D
-1.11%
1Q
-25.31%
IPO
-100.00%
Name
CNS Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-29.71%
Rev. gr., 5y
%
Revenues
0k
Net income
-19m
L+23.42%
CFO
-14m
L+33.93%
Earnings
Mar 31, 2025
Profile
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | 18,869 | 15,279 | 14,040 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (18,869) | (15,279) | (14,040) | ||||
NOPBT Margin | |||||||
Operating Taxes | 7 | 9 | |||||
Tax Rate | |||||||
NOPAT | (18,869) | (15,286) | (14,050) | ||||
Net income | (18,851) 23.42% | (15,274) 5.37% | (14,495) 53.26% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 2,318 | 16,038 | 4,654 | ||||
BB yield | -48.44% | -490.73% | -25.14% | ||||
| Debt | |||||||
Debt current | 301 | 410 | 388 | ||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | 4,092 | ||||||
Net debt | (248) | (9,645) | (4,617) | ||||
| Cash flow | |||||||
Cash from operating activities | (14,140) | (10,558) | (13,538) | ||||
CAPEX | (4) | (4) | (6) | ||||
Cash from investing activities | (4) | (4) | (6) | ||||
Cash from financing activities | 4,637 | 15,613 | 4,509 | ||||
FCF | (14,628) | (14,550) | (14,767) | ||||
| Balance | |||||||
Cash | 549 | 10,055 | 5,005 | ||||
Long term investments | |||||||
Excess cash | 549 | 10,055 | 5,005 | ||||
Stockholders' equity | (69,561) | (50,714) | (34,955) | ||||
Invested Capital | 65,429 | 59,257 | 41,965 | ||||
ROIC | |||||||
ROCE | 456.74% | ||||||
| EV | |||||||
Common stock shares outstanding | 75 | 27 | 18 | ||||
Price | 63.50 -47.08% | 120.00 -88.61% | 1,053.60 -60.54% | ||||
Market cap | 4,785 46.40% | 3,268 -82.34% | 18,511 -37.42% | ||||
EV | 4,537 | (6,377) | 13,894 | ||||
EBITDA | (18,865) | (15,267) | (14,027) | ||||
EV/EBITDA | 0.42 | ||||||
Interest | 7 | 9 | |||||
Interest/NOPBT | |||||||